Displaying 5 news results
May 21, 2021
The bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
Jul 11, 2019
The results of the LADDER trial demonstrate a major step forward but introduce many questions.
Jul 11, 2019
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
Jan 18, 2018
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
Oct 12, 2017
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing